RTP Mobile Logo
Oncology Today with Dr Neil Love: Melanoma Edition (Video Program)
Released November 2019

Featuring a roundtable discussion with Drs Jason J Luke, Michael A Postow and Ryan J Sullivan. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of melanoma.

    Until recently treatments for advanced melanoma were somewhat limited in their overall effectiveness. However, unprecedented strides have been made in defining molecular mechanisms of critical importance to melanoma development, progression and metastasis, and these have led to therapeutic advances that have completely redefined treatment algorithms and outcomes for patients. In addition, in a process similar to the drug development paradigm within which investigators are working with other solid tumors, melanoma researchers have attempted to leverage the aforementioned advances for patients with more localized presentations of the disease. This relatively sudden availability of a host of new therapies and a number of other emerging strategies that may soon join them has created a multitude of uncertainties and important clinical questions.

    To bridge the gap between research and patient care, this program features a joint discussion with 3 leading dermatology-oncology clinical investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity will assist medical oncologists with the formulation of up-to-date clinical management strategies.


    • Consider the potential risks and benefits when counseling patients about adjuvant therapy for locally advanced melanoma.
    • Use biomarkers, clinical characteristics and mutational analyses to individualize front-line and subsequent treatment approaches for patients with advanced melanoma.
    • Apply available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with BRAF mutation.
    • Identify adverse events associated with immune checkpoint inhibitors and targeted therapies for melanoma, and offer supportive management strategies to minimize or manage these side effects.
    • Evaluate emerging data with novel investigational agents and strategies demonstrating promising activity in melanoma.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of an audio component.
    CME credit is no longer available for this issue
    This CME activity consists of an video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jason J Luke, MD
    Associate Professor and Director of the Cancer Immunotherapeutics Center
    University of Pittsburgh Medical Center and Hillman Cancer Center
    Pittsburgh, Pennsylvania 

    Advisory Committee: 7 Hills Pharma LLC, Actym Therapeutics, Alphamab Oncology, Mavupharma, Pyxis Oncology, Spring Bank Pharmaceuticals, Tempest Therapeutics, TTC Oncology; Consulting Agreements: AbbVie Inc, Akrevia Therapeutics, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Compugen, EMD Serono Inc, IDEAYA Biosciences, Immunocore, Incyte Corporation, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Mersana Therapeutics, Novartis, RefleXion, Silicon Pharma, Vividion Therapeutics; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Boston Biomedical Inc, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Compugen, Corvus Pharmaceuticals, EMD Serono Inc, Evelo Biosciences, Five Prime Therapeutics Inc, Genentech, Immatics, Immunocore, Incyte Corporation, Leap Therapeutics Inc, MacroGenics Inc, Merck, Nektar, Novartis, Palleon Pharmaceuticals, RAPT Therapeutics, Spring Bank Pharmaceuticals, Tesaro, A GSK Company, Tizona Therapeutics Inc, Xencor; Ownership Interest: Actym Therapeutics, Alphamab Oncology, Mavupharma, Pyxis Oncology, Tempest Therapeutics; Travel: Akrevia Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Immunocore, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, RefleXion.

    Michael A Postow, MD
    Assistant Attending Physician
    Melanoma and Immunotherapeutics Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Aduro Biotech, Array BioPharma Inc, Bristol-Myers Squibb Company, Incyte Corporation, Merck, NewLink Genetics, Novartis; Contracted Research: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Infinity Pharmaceuticals Inc, Merck, Novartis, Rgenix.

    Ryan J Sullivan, MD
    Associate Director, Melanoma Program
    Massachusetts General Hospital Cancer Center
    Assistant Professor, Harvard Medical School
    Boston, Massachusetts

    Advisory Committee and Consulting Agreements: Array BioPharma Inc, Asana BioSciences, Bristol-Myers Squibb Company, Merck, Novartis, Replimune; Contracted Research: Amgen Inc, Merck.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Genentech, Merck and Novartis.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: November 2019
    Expiration date: November 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):